¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º z%E(o%l8  
+.~K=.O)  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ ^mL X}E]  
:#g.%&  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) ,marNG  
l :{q I#Q  
1. ICAM-1 T'}kCnp  
q;[HUyY,  
2. interleukin 12(IL-12) \d;)U4__!  
=Fc]mcJ69  
3. tumor infiltrating lymphocyte F'|K>!H  
GZi` jp  
4. TCR/CD3 complex 1?BLL;[a8  
[s$x"Ex  
5. hematopoietin receptor family VLV]e_D6s  
?;o0~][!  
6. individual idiotype(IdI) Vz0 (D  
~IYR&GEaUG  
7. integrin X'b3 CS4  
j_5&w Znq  
8. colony-stimulatory factor (CSF) AM=> P 7  
E G+/2o+W  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© qeFaY74S  
hdWVvN  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? c3GBY@m  
9n i s8  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ 7 q!==P=  
pq r_{  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠEC5 = 2w<  
uDND o  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ 5eL b/,R  
sCw>J#@2>  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) 6O,k! y>  
va_u4  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ i7- i!`<  
tl /i  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) k62s|VeU  
EpO2%|@  
3. immunoglobulin superfamily (IgSF) "f 89   
d+G%\qpzQ  
4. selectin &k,DAx`rN;  
iJE:>qOTD5  
5. anti-idiotypic antibody (¦ÁId) .'A1Eoo0d  
]B;`Jf  
6. major histocompatibility complex(MHC) q 8sfG;)  
fZ &  
7. immunotolerance ,vmn{gz  
3QBzyJW f  
8. biological reponse modifier(BRM) FS=yc.Q_  
OnE%D|Tq=  
9. immune reponse gene (Ir gene) MG=8`J-`  
Q<u?BA/  
10. reshaped antibody (or reconstituted antibody) [u!n=ev  
UL}wGWaoG  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 6d/Q"As  
*GoTN  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£  '4{=x]K  
<-?C\c~G@  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? 3s?u05_  
W;=Ae~  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ Ur]$@N   
4 j=K3m  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? }NyQ<,+mq&  
{aUTTEu  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ ^D +^~>f  
=MQ/z#:-P  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? T 4wk$R L  
2rT^OGw6  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ \Aro Sy9  
t?G6|3  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ Gu~*ZKyJ  
-MS#YcsV  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? =W3 K 6w  
 iiQn/%  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ exhU!p8  
X8ap   
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: j~{cT/5Y_  
a)ry}E =f  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ;9OhK71}  
[ - $ Do  
ÃâÒßѧ K{ar)_V/  
&$/ #"lW,V  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© RX>P-vp  
@5nFa~*K%  
1. CD8 * HKu%g  
JnsJ]_<  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) FoK2h!_  
Ldj z-  
3. immunoglobulin fold(Ig fold) 0h@FHw2d  
W91yj:  
4. cadherin (Ca-dependent cell adhesion moleculers) rz"$zc.)  
f,HUr% @  
5. idiotype-anti-idiotypic antibody immune network theory K29/7A/  
)]1hN;Nz  
6. HLA class II antigen f4f2xe7\Q  
5Kg'&B (  
7. complementarity-determining region (CDR) T^}UE<  
@z@%vr=vX  
8. perforin(or pore-forming protein ,PFP) v=N?(6T  
F[jE#M=k  
9. high affinity IL-2 receptor T`EV uRJ  
Rg?6eN  
10. artificial active immunization sAkr-x?+M  
,S-h~x  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© L80(9Y^xn  
L^+rsxR  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ&~,4$& _  
s*izhjjX  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 T D _@0Rd  
;m(iKwDt  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ >d/H4;8  
S0,\{j  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ @5%&wC  
}|P3(*S  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ _Iy\,<  
~e{ @5.g  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? ,;)ZF  
%**f`L%jN  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ]b4WfIu  
^Bx[%  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ 6}4})B2  
N^Re  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ Z>rY9VvWD  
g52a vG  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ PVCoXOqh  
.G0 N+)  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© u!_l /'\  
COrk ( V  
1. immunoglobulin gene rearrangement >yBq i^aL  
yYG<tUG;  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) U ZM #O  
K+B978XD  
3. flow cytometry(FCM) 9njwAKF?  
J!I)G&:  
4. carrier effect gAqK)@8-  
a)qan  
5. positive selection of T lymphocytes in thymus W'lqNOX[v  
yK~=6^M  
6. mouse TH1(Th1) and TH2(Th2) subsets IPiV_c-l  
{28|LwmL  
7. perforin (pore-forming protein ,PFP) Fnw:alWr  
qNp1<QO0  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) dUI5,3*  
I=Y>z ^4  
9. SH-2(src-homology region 2) xO~ ElzGm  
:+rGBkw1m  
10. Ab2¦Â (internal image) B /? L$m  
@f!X%)\;x  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© EY }:aur  
7R+(3NU1A  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? G#M)5'Q]U  
!40>LpL[  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? nB[-KS  
2G8pDvBr  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ1J@Iekat  
2ZH+fV?.  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ {pzj@b 1S  
cs9^&N:w[  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠIgT`on3Y  
d|`Ll  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) *6uccx7{  
ITu19WG  
ÃâÒßѧרҵ£º [3% mNNk  
s?SspuV  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ /@os*c|je  
J 3!~e+wn  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? R[WiW RfD  
S63 Zk0(25  
´«È¾²¡Ñ§×¨Òµ£º ?b7\m":'  
8fR(y~_gF  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ @KG0QHyiU  
y(A' *G9  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ c:[k+_Zr  
Z$oy;j99y  
Ïû»¯×¨Òµ£º E?m~DYnU  
\&  JZ >h  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ ?Ua,ba*  
<@<rU:o=V  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? _z5/&tm_H  
`-NK:;^  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ MNT~[Z9L5G  
Cu "Cpt[  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© %>_[b,  
|dRVSVN  
1. Fas(CD95)/FasL Ob d n#Wm=  
k.T=&0J_1  
2. common chain of cytokine receptor Z%T Ajm  
|diI(2w  
3 . TCR/CD3 complex Vn s3859$8  
Aoa8Q E   
4. negaive selection of thymocytes ZsGvv]P  
_0/unJl`  
5. artificial active immune K+g[E<x\=  
6Z\aJ  
6. anti-idiotypic Z:4/lx7Bq  
 tm1 =  
7. IgSF Mk! Fy]3  
l.YE@EL  
8. Integrin F!z0N&#  
1$E(8"l  
9. chemokine 3i^X9[.  
]>3Y~KH(  
10. B7/CD28 3o.x<G(  
I8H3*DE  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© W"{Ggk `  
hCxg6e<[  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ y:G%p3h)[  
E0HqXd?  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ Q3@zUjq_Q  
zAgX{$/Fg  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ xd Z$|{,  
mxNd  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ LI,wSTVjC  
1M ?BSH{  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ z?/_b  
3(YvqPp&  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ IZVP-  
{3Inj8a=?A  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© ZmK=8iN9J  
)~2\4t4|g  
1. B7/CD28 >ohCz@~  
N8A)lYT]_u  
2. Th1 subset s$Vl">9#  
zs$r>rlO  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© 9A |A@E#  
7x)Pt@c  
4. antibody affinity maturation *85N_+Wv!  
O9ex=m `L  
5. AP-1 m*^)#  
<4r8H-(%  
6. single chain variable fragment£¨ScFv£© !GOaBs  
2z>-H595az  
7. NK cell receptor b{0a/&&1O  
G`!x+FB  
8. Zinkernagel-Doherty phenomenon *g5bdQ:Av~  
N{J 1C6  
9. Ig fold !Asncc G  
_CD~5EA:  
10. CD40/CD40L 2A_1E \  
r]9-~1T  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© s|C[{n<_  
\'|n.1Fr  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ e=;A3S  
i6Z7O )V  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ w/@ZPBRo]  
}s,NM%oI  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ f:Pl Mv!{  
T  Q41i/{  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ }c G)$E  
ns~]a:1yh  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ a1pp=3Pd?~  
@=kg K[t 9  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ )kep:-wm  
v_KO xV:<`  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ =$OGHc  
,Zmjw@ w  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© ;nS F\X(;{  
x-i1:W9;  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© *}2L4]  
oq7G=8gTp  
1.Co-stimulators (or co-stimulating molecules) >/ay'EyY;>  
m > =DJ{KQ  
2.NK-kB ///Lg{ ie  
7y$\|WG?!r  
3.Immunoglobulin superfamily ^kfqw0!  
Kk^*#vR  
4.antigen-presenting cell (APC) "t^v;?4  
WEwa<%Ss  
5.death domain PC9,;T&7_  
SnE^\I^ O  
6.CCR and CXCR xhP~]akHN7  
vAX(3  
7.Lectin (or mitogen) ;<Q%d~$xy}  
k6CXuU  
8.Clusters of differentiation, CD) H,}&=SCk  
%,bD| NKp  
9.B7 family l~E~!MR  
e |Ri  
10.Cytotoxic T lymphocyte, CTL) 2 GRI<M  
>NUbk9}J4  
11.IL-15 and IL-15 receptor (IL-15R) krfXvQJwJ  
;TL.QN/l  
12.MHC restriction 8e?/LA%MU  
%jHm9{|X  
13.Affinity-chromatography 7IxeSxXH  
JY  
14.Cyctosprin A, CsA 7I;kh`H$(f  
'?C6P5fm  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) iTHwH{!  
G[KjK$.Ts?  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© -+ByK#<%  
vh\i ^  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 nkHl;;WJ  
L"ho|v9:  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ z_> ~=Mm  
n%3!)/$  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ C&z!="hMhR  
g@#he95 }  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© 8~(xi<"e  
%"`p&aE:  
ÃâÒßѧרҵ£º 1h@qcom9K_  
+JEr c)%  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ 5&8E{YXr  
Y|R=^ =d\  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ `Moo WG  
eDpi0htm  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ GDLi ?3q  
Nk9= A4=|  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) D=ej%]@iw  
4.,EKw3  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) Zbnxs.i!  
d&^b=d FDu  
1. ADCC(antibody dependent cell-mediated cytotoxicity) eV"%(<{  
xVP SL#>  
2. »·æß¾úËØ(cyclosporin) jz f~n~  
|*?N#0s5h  
3. KIR(killer cell inhibitory receptor) [ bnu DS  
s:_hsmc"  
4. HLDA(human leucocyte differentiation antigen) mW{;$@PLF"  
w"0$cL3  
5. Interleukin 18(IL-18) eP2Q2C8g  
k*A(7qQA`4  
6. ÕûºÏËØ(integrin) <pk*z9   
g/C 7wc  
7. Fas/FasL _-fLD  
3.YH7rN  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) OD'~t,St  
O ?T~>|  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) d_ =K (}eR  
SL uQv?R}9  
10. Th1/Th2 Qb@j8Xa4[  
7ZI{A*^vB  
11. »ùÒòÒßÃç(DNAÒßÃç) ai?uJ}  
P{dR pH|  
12. chemokines and chemokine receptor U>t:*SNC*  
VQ!4( <XD  
13. ÃâÒßÄÍÊÜ |!K&h(J|  
Y<;C>Rs  
14. ¹²´Ì¼¤·Ö×Ó L\ysy2E0  
c+{XP&g8_J  
15. ËÀÍö½á¹¹Óò(death domain) DQhHU1  
m:Rx<E E  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) Yy 4Was#  
^Whc<>|  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? NH/jkt&F[  
4`~OxL  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ2h5T$[fV  
e~QLzZ3  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î [ 2@Lc3<  
W9cvxsox  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ ,=!s;+lu{  
a:|]F|  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå Q3lVx5G>4  
~i^,Z&X:  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ IAd ^$9  
WV}pE~  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) l$BKE{rg  
/X R gsF  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ i_6wD  
(`n*d3  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ @TKQ_7BcB  
?fs#K;w  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»